Informations générales (source: ClinicalTrials.gov)
Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -A Pilot Study WP3 P003 (PharmacogWP3)
Interventional
N/A
University Hospital, Lille (Voir sur ClinicalTrials)
mai 2017
décembre 2020
29 juin 2024
In the perspective to better evaluate the efficacy of new treatment strategies for
Alzheimer disease (AD), it appears important to develop experimental paradigms to
precisely measure cognitive endpoints/biomarkers that may be used in healthy volunteers
as tools to validate drug efficacy profile.
The use of Electroencephalography (EEG) may be, therefore, a good candidate. The purpose
of the present study is to use EEG to more precisely explore cognitive processes in
healthy subjects, with a particular interest in episodic and working memory functions
that are usually altered in both AD and Mild Cognitive Impairment (MCI) as well as to
better understand underlying neural mechanisms involved in these processes.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital Cardiologique, CIC - Lille - France | Contact (sur clinicalTrials) | ||||
Critères
Homme
Inclusion Criteria:
- Right-handed
- In good health on the basis of the medical interview (medical history, symptoms),
the physical examination and vital signs
- Non smoker and with no history of drug or alcohol abuse
- Without chronic treatment
- With normal hearing and normal vision including color (with correction)
- French speaker and able to understand the test instructions
- Has provided written informed consent
- Able to read and understand the Information Form and comply with the protocol
instructions and restrictions
- Right-handed
- In good health on the basis of the medical interview (medical history, symptoms),
the physical examination and vital signs
- Non smoker and with no history of drug or alcohol abuse
- Without chronic treatment
- With normal hearing and normal vision including color (with correction)
- French speaker and able to understand the test instructions
- Has provided written informed consent
- Able to read and understand the Information Form and comply with the protocol
instructions and restrictions
- Cognitive impairment (MoCA < 26)
- Cognitive complaint (MacNair Scale > 15)
- History of brain disease (severe brain trauma, stroke, cerebral tumor...) or current
cerebral disease
- Major medical or surgical history
- Current chronic disease
- Vascular or metabolic risk factor
- History or current mental disease or addiction (MINI)
- Family history of young onset dementia
- Family history of chronic or severe neurological or mental disease (first degree
relatives)
- In the opinion of the investigator, is unlikely to comply with the study protocol or
is unsuitable for any other reason
- Participates to another clinical trial or is still being within a washout period of
a previous clinical trial
- Already exposed to cognitive tests used in this study.